<DOC>
	<DOCNO>NCT00774696</DOCNO>
	<brief_summary>The objective study compare relative bioavailability clarithromycin 500 mg tablet ( Ranbaxy Laboratories Limited ) BIAXIN® 500 mg tablet healthy , adult subject non-fasting condition .</brief_summary>
	<brief_title>Bioequivalence Study Clarithromycin 500 mg Tablets Under Non-Fasting Conditions</brief_title>
	<detailed_description>The study conduct open label , balance , randomise , two-treatment , two-period , two-sequence , single-dose , crossover , bioavailability study clarithromycin formulation compare clarithromycin 500mg tablet Ranbaxy Laboratories Biaxin® tablet 500mg ( contain clarithromycin 500 mg ) healthy , adult , human , male subject feed condition Subjects give standardized meal start 30 minute assign dose time consist one buttered English muffin , one fry egg , one slice American cheese , one slice Canadian bacon , 2.45 ounce hash brown potato , six fluid ounce orange juice , eight fluid ounce whole milk . A single oral dose clarithromycin 500mg administered period supervision train Medical Officer . During course study , safety parameter include vital sign , physical examination , medical history , clinical laboratory safety test ( haematology , biochemical parameter ) assess , clinical laboratory safety test ( hematology &amp; biochemical parameter ) perform end study .</detailed_description>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>1 . Source Subjects : Noninstitutionalized subject consist member community large . 2 . Characterization Study Group All subject select study least 18 year age . Female subject must unable become pregnant ( postmenopausal least 1 year , surgically sterile ) . Each subject shall give general physical examination within 28 day initiation study . Such examinati°n include , limited , blood pressure , general observation , history . Each female subject give serum pregnancy test part prestudy screen process . At end study , subject exit evaluation consist interim history , global evaluation , clinical laboratory measurement . Adequate blood urine sample obtain within 28 day begin first period end trial clinical laboratory measurement . Drags Abuse Screen : prestudy checkin study period subject select normal . Electrocardiograms participate subject record initiation study file Subject 's case report form . 1 . Subjects history chronic alcohol consumption ( past 2 year ) , drug addiction , serious gastrointestinal , renal , hepatic cardiovascular disease , tuberculosis , epilepsy , asthma ( past 5 year ) , diabetes , psychosis glaucoma eligible study . 2 . Subjects whose clinical laboratory test value great 20 % outside normal range may retested . If clinical value outside range retesting , subject eligible participate study unless clinical investigator deem result significant . 3 . Subjects history allergic response theclass drag test ( include penicillin product ) exclude study . 4 . All subject urine sample assay presence drug abuse part clinical laboratory screening procedure checkin study period . Subjects find urine concentration test allowed participate . 5 . Subjects donate blood plasma least ( 30 ) day prior first dose study . g. Female subject pregnant able ( woman child bear potential ) become pregnant study allow participate . h. All female subject screen pregnancy check study period . Subjects positive pr inconclusive result withdraw study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Bioequivalence study clarithromycin</keyword>
</DOC>